Experience. Expertise. Resources.
DPAc is a new model for developing truly innovative medicines. It is based on creating a true partnership between world-class academics and the industry-leading scientists of GSK.
The academic researcher supplies depth of scientific knowledge, creativity and a novel concept. The DPAc team provides drug discovery and development experience, applied research expertise and the considerable resources of GlaxoSmithKline (GSK) R&D.
GSK is a science-led global healthcare company that researches and develops innovative medicines and brands. Our products are used by millions of people around the world to improve human health. There are more than 99,000 people in 115 countries on the GSK team. More than 12,500 of them are involved in research.
GSK has a full and diverse product development pipeline, including new chemical entities, biological entities and vaccines, new drug combinations and new indications for existing compounds. In 2012 alone, US and EU regulatory agencies approved 8 GSK medicines. Additionally, GSK filed applications for approval of 6 unique new medicines, and delivered full clinical data packages for an additional 14 medicines. We initiated late stage clinical testing on another two novel therapeutics. When GSK discovers or licenses a high potential clinical candidate, we have the resource, innovation and inspiration to turn it into a medicine and bring it to the patient.